{4 (risedronate sodium 35 MG Delayed Release Oral Tablet) } Pack [Atelvia]
risedronate sodium
RxCUI: 1020066
What the CMS Formulary Data Shows for {4 (risedronate sodium 35 MG Delayed Release Oral Tablet) } Pack [Atelvia]
Per the CMS 2026 Part D formulary file, {4 (risedronate sodium 35 MG Delayed Release Oral Tablet) } Pack [Atelvia] (RxNorm concept RXCUI 1020066, generic name risedronate sodium) appears on 1 distinct formulary file spanning 2 Medicare Part D plan offerings - 0% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 1, with a cross-plan average of Tier 1.
Real-world access to {4 (risedronate sodium 35 MG Delayed Release Oral Tablet) } Pack [Atelvia] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 100% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 117 Part D beneficiaries filled {4 (risedronate sodium 35 MG Delayed Release Oral Tablet) } Pack [Atelvia] in 2023, with total plan-and-beneficiary spending of $223,816 and an average per-beneficiary annual cost of $1,912.96. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry {4 (risedronate sodium 35 MG Delayed Release Oral Tablet) } Pack [Atelvia] today.
Coverage Details
- Formularies covering
- 1
- Plans covering
- 2
- Coverage rate
- 0%
- Tier range
- Tier 1, Preferred Generic
- Average tier
- Tier 1, Preferred Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 100% of formularies
2023 Medicare Spending
- Beneficiaries
- 117
- Total spending
- $223,816
- Avg per beneficiary
- $1,912.96
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering {4 (risedronate sodium 35 MG Delayed Release Oral Tablet) } Pack [Atelvia]
2 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Hamaspik Medicare Choice (HMO D-SNP) | HAMASPIK, INC. | T1 | No | $0 | NY |
| Hamaspik Medicare Select (HMO D-SNP) | HAMASPIK, INC. | T1 | No | $34.50 | NY |
Frequently Asked Questions
Is {4 (risedronate sodium 35 MG Delayed Release Oral Tablet) } Pack [Atelvia] covered by Medicare Part D?
Yes, {4 (risedronate sodium 35 MG Delayed Release Oral Tablet) } Pack [Atelvia] is covered by 2 Medicare Part D plans (0% of all Part D formularies).
What tier is {4 (risedronate sodium 35 MG Delayed Release Oral Tablet) } Pack [Atelvia] on Medicare Part D plans?
{4 (risedronate sodium 35 MG Delayed Release Oral Tablet) } Pack [Atelvia] averages Tier 1 across Part D plans, ranging from Tier 1 to Tier 1.
Does {4 (risedronate sodium 35 MG Delayed Release Oral Tablet) } Pack [Atelvia] require prior authorization?
0% of Part D formularies require prior authorization for {4 (risedronate sodium 35 MG Delayed Release Oral Tablet) } Pack [Atelvia]. Step therapy: 0%. Quantity limits: 100%.
How much does Medicare spend on {4 (risedronate sodium 35 MG Delayed Release Oral Tablet) } Pack [Atelvia]?
In 2023, total Medicare Part D spending on {4 (risedronate sodium 35 MG Delayed Release Oral Tablet) } Pack [Atelvia] was $223,816, covering 117 beneficiaries. The average spend per beneficiary was $1,912.96.
Read our methodology - how this data is sourced, computed, and verified.